Piper Sandler initiated coverage of Relmada Therapeutics (RLMD) with an Overweight rating and $12 price target The firm says the company is advancing NDV-01, a novel intravesicle treatment for non-muscle invasive bladder cancer with “several key advantages” versus existing options. These include the benefits of chemo combination therapy and sustained-release formulation for increased exposure, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD:
- Relmada Therapeutics Charts Aggressive Path After Earnings Call
- Relmada Highlights NDV-01 Data, Funding in 2025 Results
- Relmada Therapeutics price target raised to $19 from $10 at Mizuho
- Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors
- Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD